[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Italiano de Buenos Aires\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":423},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,47,75,98,123,149,173,200,224,273,297,318,343,365,393],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643335","phase-2-subanesthetic-ketamine-infusions-for-depressive-symptoms-in-intensive-care-unit-patients-100643335",false,"NCT07639359","Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients","Ketamine In Depression - Intensive Care Unit Trial (KID-ICU): A Phase II Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Ketamine Infusion for Depressive Symptoms in Intensive Care Unit Patients","KID-ICU","\\*\\*Inclusion Criteria:\\*\\*\n\n* Age 18 to 99 years.\n* Male or female.\n* Admission to an intensive care unit for 6 or more days at the time of screening.\n* Moderate to severe depressive symptoms, defined as a Patient Health Questionnaire-9 score of 10 or greater at screening.\n* Ability to provide informed consent.\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n* History of psychosis or hallucinations, as assessed by review of the electronic medical record and patient interview during screening.\n* History of prolonged QT interval.\n* History of dementia.\n* History of major depressive disorder before the current intensive care unit admission.\n* History of psychiatric diagnosis, including dissociative disorder, primary psychotic disorder, mania with psychosis, pervasive developmental disorder, cognitive disorder, or anorexia nervosa.\n* Known allergy to ketamine or diphenhydramine.\n* History of increased intracranial pressure, hypertensive hydrocephalus, or increased intraocular pressure.\n* Hemodynamic instability at the time of screening, defined as peripheral oxygen saturation \\\u003C95%, systolic blood pressure \\\u003C90 mmHg or \\>180 mmHg, heart rate \\\u003C50 or \\>120 beats\u002Fmin, or respiratory rate \\\u003C10 or \\>30 breaths\u002Fmin.\n* Patient refusal to participate or to provide informed consent.\n* Pregnancy, postpartum period within 2 months, or breastfeeding.\n* Presence of intracranial mass or vascular lesion.\n* Altered mental status precluding informed consent.\n* Body weight \\>115 kg or \\\u003C45 kg.\n* Active psychosis.\n* Current treatment with medications that may interfere with the N-methyl-D-aspartate receptor system, including lamotrigine, acamprosate, memantine, riluzole, or lithium.\n* Current treatment with aminophylline or theophylline.\n* Active substance withdrawal or use of hallucinogens, including cannabis, in the past month, as determined by clinical interview and urine drug screening.","ALL","18 Years","99 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","\\*\\*Brief Summary\\*\\*\n\nDepressive symptoms are frequent among patients admitted to the intensive care unit (ICU) and may be associated with worse clinical outcomes, reduced participation in care, lower treatment adherence, and increased mortality. Conventional antidepressants, including selective serotonin reuptake inhibitors (SSRIs), have limited utility in this setting because of their delayed onset of action, incomplete efficacy, and potential drug interactions in medically complex patients.\n\nKetamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has emerged as a rapid-acting antidepressant when administered at subanesthetic doses. Preliminary evidence suggests that intravenous ketamine may improve mood-related symptoms within a short time frame and may have an acceptable safety profile in selected critically ill patients.\n\nThe KID-ICU trial (Ketamine In Depression - Intensive Care Unit) is a Phase II randomized, double-blind, placebo-controlled multicenter trial designed to evaluate the efficacy and safety of subanesthetic intravenous ketamine infusions for moderate-to-severe depressive symptoms in adult ICU patients. Eligible participants are adults who have been admitted to the ICU for 6 or more days and have moderate-to-severe depressive symptoms, defined as a Patient Health Questionnaire-9 (PHQ-9) score of 10 or greater.\n\nParticipants will be randomized in a 1:1 ratio to receive either intravenous ketamine at 0.5 mg\u002Fkg, with a maximum dose of 60 mg per day, administered over 40 to 60 minutes on 2 consecutive days, or placebo with normal saline in an identical presentation. The primary efficacy outcome is the change in PHQ-9 score from baseline to Day 30 after the last infusion. Safety outcomes include prespecified hemodynamic, neuropsychiatric, and treatment-discontinuation events during and after infusion. Secondary outcomes include anxiety and depression symptoms assessed with the Hospital Anxiety and Depression Scale (HADS), clinical severity and improvement assessed with Clinical Global Impression scales, intensive care unit and hospital length of stay, and mortality.\n\nA total of 50 participants will be enrolled across intensive care unit sites at Hospital Italiano de Buenos Aires. Psychiatric and clinical follow-up will be provided to all participants regardless of treatment assignment.",[28,29],"Depression Disorder","Ketamine",[31,32,33],"ketamine","intensive care","depression","RECRUITING","2026-06-05",{"date":37,"type":38},"2026-06-10","ACTUAL",{"date":40,"type":38},"2026-05-14",{"date":42,"type":22},"2027-10-01",{"name":44,"class":45},"Hospital Italiano de Buenos Aires","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100643747","low-grade-gliomas-in-argentina-incidence-survival-and-therapeutic-strategies-100643747","NCT07631338","Low-grade Gliomas in Argentina: Incidence, Survival, and Therapeutic Strategies","Study population cohort 1\n\n* Inclusion Criteria\n\n  * Adult patients (≥18 years old) affiliated to the health plan of Hospital Italiano de Buenos Aires.\n  * Documented clinical follow-up of at least 1 year during the study period.\n* Exclusion Criteria\n\n  * Patients not affiliated to the health plan of the Hospital Italiano de Buenos Aires.\n\nStudy population cohort 2\n\n* Inclusion Criteria\n\n  * Adult patients (≥18 years) with histopathologically confirmed diagnosis of low-grade glioma (WHO grades I and II).\n* Exclusion Criteria\n\n  * Incomplete or doubtful diagnosis based on histopathologic and molecular criteria.",{"count":54,"type":22},40,"OBSERVATIONAL","Low-grade gliomas (LGG) are slow-growing primary brain tumors (WHO grades I-II), and their incidence, survival, and treatment patterns in middle-income settings such as Argentina remain poorly characterized. This retrospective, multicenter study comprises two complementary cohorts:\n\n1. Cohort 1: The \"captive\" population covered under the Hospital Italiano de Buenos Aires Health Plan (January 2011-December 2023) to estimate LGG incidence density.\n2. Cohort 2: Histologically confirmed LGG patients treated at the major referral centers to describe overall survival (OS) and disease-free survival (DFS) at 1 and 5 years.\n\nDemographic, clinical, pathological, and treatment data will be collected in a centralized REDCap database.\n\nThe primary objective is to describe LGG incidence in Argentina and estimate survival using Kaplan-Meier curves. The secondary objectives include characterizing therapeutic strategies, molecular mutations, and prognostic factors through Cox regression analysis. This registry will fill a critical gap in LGG epidemiology in middle-income countries and generate hypotheses for future research.",[58],"Low-grade Glioma",[60,61,62,63,64,65],"Low-grade glioma","Glioma","Brain tumor","Neuro-oncology","Incidence","Survival","2026-06-01",{"date":68,"type":38},"2026-06-08",{"date":70,"type":38},"2026-04-01",{"date":72,"type":22},"2027-05-31",{"name":44,"class":45},6,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100638529","cryotherapy-versus-standard-care-in-reducing-opioid-consumption-after-total-knee-arthroplasty-100638529","NCT07630337","Cryotherapy Versus Standard Care in Reducing Opioid Consumption After Total Knee Arthroplasty","Efficacy of Cryotherapy Versus Standard Care in Reducing Opioid Consumption After Total Knee Arthroplasty: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 60 and 80 years\n* Scheduled to undergo primary total knee arthroplasty for knee osteoarthritis\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Revision total knee arthroplasty\n* Vascular disorders affecting the lower limbs\n* Body mass index (BMI) greater than 35 kg\u002Fm²\n* Active knee infection\n* Severe preoperative limitations in knee mobility",{"count":83,"type":22},74,[85],"NA","The goal of this clinical trial is to learn if compressive cryotherapy can reduce postoperative opioid consumption in patients undergoing primary total knee arthroplasty. It will also evaluate whether compressive cryotherapy improves postoperative recovery compared with standard care using conventional ice application. The main questions it aims to answer are:\n\nDoes compressive cryotherapy reduce the total consumption of opioids during the first 7 days after total knee arthroplasty?\n\nDoes compressive cryotherapy reduce postoperative pain and improve early recovery compared with standard cryotherapy?\n\nResearchers will compare compressive cryotherapy using the Game Ready® device with standard care using traditional ice packs to determine whether the intervention reduces opioid consumption and improves postoperative outcomes.\n\nParticipants will:\n\nBe randomly assigned to receive compressive cryotherapy or standard cryotherapy with ice packs after surgery.\n\nApply the assigned treatment four times per day during the first 7 postoperative days.\n\nRecord daily pain levels using a visual analog scale (VAS) and document opioid consumption in a pain diary.\n\nAttend a follow-up visit on postoperative day 7 for evaluation of knee swelling, hematoma size, and recovery using the QoR-15 questionnaire.",[88,89,90],"Osteoarthritis, Knee","Postoperative Pain","Total Knee Arthroplasty",{"date":35,"type":38},{"date":93,"type":38},"2026-02-01",{"date":95,"type":22},"2027-06-01",{"name":44,"class":45},1,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":106,"conditions":107,"keywords":113,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":74},"100637877","effect-of-protein-dosage-on-persistent-acute-renal-failure-in-critically-ill-patients-100637877","NCT07631221","Effect of Protein Dosage on Persistent Acute Renal Failure in Critically Ill Patients.","Inclusion Criteria:\n\n* Patients aged 18 years or older admitted to the ICU.\n* Patients receiving exclusive enteral or parenteral nutrition\n* Acute kidney injury or exacerbated chronic kidney disease according to KDIGO criteria (increase in creatinine greater than 0.3 mg\u002FdL in less than 48 hours or a 1.5-fold increase in baseline creatinine in 7 days)\n\nExclusion Criteria:\n\n* Patients diagnosed with chronic kidney disease with a creatinine clearance of less than 30 ml\u002Fmin\u002Fm2 or on dialysis at admission.\n* Patients with a history of kidney transplantation\n* Patients with severe liver disease (Child-Pugh score \\>7 points)\n* Patients with acute kidney injury undergoing renal replacement therapy at T0\n* BMI\\> 30",{"count":105,"type":22},344,"Background:\n\nAcute kidney injury (AKI) is common in critically ill patients and is associated with worse outcomes, including longer ICU stay, need for dialysis, and higher mortality. Patients with AKI often experience significant protein and calorie loss due to their illness and medical treatments. Providing the right amount of protein may help maintain muscle mass and improve recovery; however, consuming too much protein could potentially worsen kidney function. Current international guidelines recommend adequate protein intake, but the best dose remains uncertain, especially for patients with AKI.\n\nStudy Purpose:\n\nThis research will examine whether patients with AKI who receive a higher protein intake (greater than 1.2 g\u002Fkg\u002Fday) have different outcomes compared to those who receive a standard or lower protein intake (≤1.2 g\u002Fkg\u002Fday). The primary outcome is whether a higher protein intake leads to a longer recovery time from AKI or worsens kidney function.\n\nStudy Design:\n\nThis is a retrospective, multicenter study using data from five hospitals in Argentina. It is designed as a \"target trial emulation,\" meaning researchers will analyze existing patient data as if it were a randomized clinical trial. Patients will be included on the fifth day of their ICU stay and classified into two groups based on their protein intake on day 5:\n\n* Group 1 (Standard Protein): ≤1.2 g\u002Fkg\u002Fday\n* Group 2 (High Protein): \\>1.2 g\u002Fkg\u002Fday No additional interventions will be performed; data are collected from medical records.\n\nStudy Population:\n\nThe study will include adult patients (≥18 years) admitted to the ICU who are receiving exclusive enteral or parenteral nutrition and have AKI (or worsening chronic kidney disease) according to KDIGO criteria. Patients with advanced chronic kidney disease (creatinine clearance \\\u003C30 ml\u002Fmin\u002F1.73 m²) or undergoing hemodialysis at T0, previous kidney transplant, severe liver disease, or BMI \\>30 will be excluded.\n\nOutcomes:\n\n* Primary Outcome: Time to recovery of kidney function within 30 days, measured by creatinine returning close to baseline values.\n* Secondary Outcomes: Changes in blood urea levels, duration of renal replacement therapy (hemodialysis), ICU length of stay, and 30-day mortality.\n\nStatistical Approach:\n\nTo minimize bias, the study will use advanced statistical methods, including propensity score weighting, to ensure fair comparison between groups. Competing risks (such as death before kidney recovery) will be taken into account in the analysis.\n\nSignificance:\n\nThis study will provide important information about the safety and effectiveness of higher protein intake in critically ill patients with AKI. The findings may help guide nutritional strategies in the ICU, optimize kidney outcomes, and improve patient care.",[108,109,110,111,112],"Acute Kidney Failure","Critical Illness","Protein Intake","Nutritional Support","Mortality in Intensive Care Units",[114,109,110,115,116,111],"Acute Kidney Injury","Target Trial Emulation","Intensive Care Unit",{"date":35,"type":38},{"date":119,"type":38},"2025-09-15",{"date":121,"type":22},"2026-12-01",{"name":44,"class":45},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":46},"100637759","study-of-adult-patients-residing-in-argentina-diagnosed-with-type-2-diabetes-treated-with-a-new-formulation-of-semaglutide-both-oral-and-subcutaneous-in-a-real-world-setting-at-3-months-6-months-and-1-year-of-follow-up-quantifying-the-reduction-in-glycated-hemoglobin-100637759","NCT07621419","Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin","New Formulation of Semaglutide in the Treatment of Type 2 Diabetes in Argentina: a Prospective, Multicenter, Real-world Study","SEMA-REAL ARG","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of type 2 diabetes mellitus.\n* Baseline glycated hemoglobin (HbA1c) \\>7% and ≤12%.\n* Initiating treatment with semaglutide (oral or subcutaneous) prescribed by the treating physician according to clinical judgment.\n\nExclusion Criteria:\n\n* Pregnancy or lactation at the time of enrollment.\n* History of severe hypersensitivity or adverse reactions to glucagon-like peptide-1 (GLP-1) receptor agonists.\n* Contraindications to semaglutide as listed in the product label (e.g., severe gastrointestinal disease, certain endocrine tumors).\n* Any other serious medical condition that, in the investigator's opinion, may interfere with study participation or data interpretation.",{"count":132,"type":22},145,"The goal of this prospective, multicenter, observational study is to evaluate the real-world effectiveness and safety of oral and subcutaneous semaglutide in adults with type 2 diabetes mellitus in Argentina. The main objective is to assess changes in glycated hemoglobin (HbA1c) from baseline to 3, 6, and 12 months after treatment initiation. Secondary objectives include evaluating changes in body weight, waist circumference, hand-grip strength, treatment satisfaction, medication adherence, treatment route switching, treatment discontinuation, and adverse events.\n\nParticipants will receive semaglutide as prescribed by their treating physician as part of routine clinical care. Follow-up assessments will be performed at 3, 6, and 12 months to collect clinical, laboratory, safety, treatment satisfaction, and adherence data. Treatment satisfaction will be assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ), and adherence will be assessed using the Simplified Medication Adherence Questionnaire (SMAQ).",[135],"Diabetes Mellitus",[137,138,139,140,141],"semaglutide","real world study","obesity","type II diabetes","Argentinian Society of Medicine",{"date":143,"type":38},"2026-06-02",{"date":145,"type":38},"2025-08-04",{"date":147,"type":22},"2028-12-31",{"name":44,"class":45},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":160,"studyType":55,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":97},"100269008","epidemiological-and-molecular-colorectal-cancer-registry-100269008","NCT02781337","Epidemiological and Molecular Colorectal Cancer Registry","EMR-CRC","Inclusion Criteria:\n\n* Adult patients undergoing colorectal surgery for colorectal cancer.\n\nExclusion Criteria:\n\n* Unwillingness to participate.","21 Years","96 Years",{"count":159,"type":22},2100,"10 Years","This is a Registry that invites patients undergoing colorectal surgery for colorectal cancer. Epidemiological data is collected. The Registry includes tumor tissue and blood banks for analyzing different genetic mutations and disease-specific biomarkers.",[163,164],"Colorectal Neoplasms","Colorectal Cancer","2026-04-30",{"date":167,"type":38},"2026-05-01",{"date":169,"type":4},"2012-05",{"date":171,"type":22},"2033-12",{"name":44,"class":45},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":23,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":199,"locationsCount":4},"100623498","impact-of-implementing-a-rapid-pcr-based-algorithm-for-carbapenemase-producing-enterobacterales-cpe-and-infection-control-bundle-in-a-tertiary-hospital-100623498","NCT07397416","Impact of Implementing a Rapid PCR-based Algorithm for Carbapenemase-producing Enterobacterales (CPE) and Infection Control Bundle in a Tertiary Hospital","Intervention in the CPE Surveillance Algorithm and Isolation Re-evaluation With the Addition of PCR vs. Culture-based Protocol: Real-life Time Differences","Inclusion Criteria:\n\n* Adult patients aged ≥18 years\n* Patients screened for carbapenemase-producing Enterobacterales (CPE) carriage by perianal swab within the first 5 days of hospital admission\n* Patients newly identified as CPE-colonized, leading to initiation of contact isolation\n* Patients found to be decolonized, leading to discontinuation of contact isolation\n* Patients with indication for active surveillance at hospital admission:\n\n  * Transfer from another healthcare facility\n  * Hospitalization in another healthcare center within the previous month\n* Patients undergoing active surveillance during hospitalization:\n\n  * First surveillance swab in high-risk neutropenic patients (HAR flag)\n  * First surveillance swab in immunosuppressed units, such as hematopoietic stem-cell transplant wards\n* Patients evaluated for discontinuation of contact precautions who meet all of the following:\n\n  * Prior CPE-positive surveillance sample\n  * At least 3 months since the last positive result and last hospitalization\n  * No systemic antibiotic exposure during that period\n\nExclusion Criteria:\n\n* Lost samples\n* Insufficient samples\n* Invalid laboratory test results requiring repeat sampling",{"count":181,"type":22},800,[85],"Purpose:\n\nCarbapenemase-producing Enterobacterales (CPE) are a growing cause of healthcare-associated infections, linked to high morbidity, mortality, and cost. Current screening methods rely mainly on culture, which can take up to 48 hours and delay infection control actions.\n\nThis study aims to evaluate the real-life impact of implementing a rapid PCR-based algorithm for CPE detection compared with the standard culture-based protocol, focusing on time differences in isolation and de-isolation decisions in hospitalized patients.\n\nDesign:\n\nA quasi-experimental, before-and-after, retrospective study conducted at Hospital Italiano de Buenos Aires (HIBA).\n\nPrimary Outcome:\n\nTime (in hours) between rectal swab request and change in isolation status (application or removal of isolation label) before and after PCR implementation.\n\nPopulation:\n\nAdult patients (≥18 years) admitted between October 2023-April 2024 (pre-intervention) and October 2024-April 2025 (post-intervention), who had contact isolation initiated or discontinued based on CPE surveillance results.\n\nRationale:\n\nThe introduction of rapid molecular testing could reduce operational delays and unnecessary isolation days, optimizing resource use in a setting with high CPE endemicity.",[185],"Carbapenemase-Producing Enterobacterales (CPE) Colonization",[187,188,189,190,191],"Healthcare-Associated Infections","Antimicrobial Resistance","Enterobacteriaceae Infections","Nosocomial Colonization","Infection Control","NOT_YET_RECRUITING","2026-02-04",{"date":195,"type":38},"2026-02-09",{"date":197,"type":22},"2026-03-01",{"date":167,"type":22},{"name":44,"class":45},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":97},"100159358","hiba-institutional-registry-of-amyloidosis-100159358","NCT01347047","HIBA-Institutional Registry of Amyloidosis","Institutional Registry of Amyloidosis (Hospital Italiano de Buenos Aires)","RIA-HIBA","Cases of amyloidosis are captured by electronic medical records whenever the physician register amyloidosis as a patient diagnosis, and\u002For there is amyloidosis in a biopsy specimen and\u002For requests for the following studies of an adult patient: plasma kappa and lambda light-chain concentrations, the kappa: lambda ratio, transthoracic Doppler echocardiography, or cardiovascular magnetic resonance examination or pyrophosphate scintigraphy From the possible cases included in the IRA, a prospective review of the electronics health records was performed to confirm the presence of amyloidosis\n\n\\*\\*Inclusion Criteria: 1 AND (2 or 3)\n\n1. Patients over 18 years:\n2. Confirmed amyloidosis: Proof of deposit of amyloid pathology by tissue biopsy in abdominal fat, bone marrow, rectum or organ involved (eg, kidney, liver, sural nerve)\n3. Clinically compatible case of Amyloidosis :\n\n   * Exclusion Criteria:\n\nRefusal to participate in the study or the informed consent process by the patient or legal representative or refusal to consent to participate in the study in the case of minors.",{"count":209,"type":22},500,"1. Creating a population-based registry system Amyloidosis prospective epidemiological survey\n\n   * risk factors\n   * diagnosis\n   * prognosis\n   * treatment\n   * monitoring\n   * survival\n2. Describe the occurrence of amyloidosis in the population of HIBA, Hospital Italiano de Buenos Aires.\n3. Describe the characteristics of clinical presentation, evolution and predisposing factors of amyloidosis.",[212],"Amyloidosis",[212,214,215],"Known or Suspected","rare diseases","2026-01-20",{"date":218,"type":38},"2026-01-22",{"date":220,"type":38},"2011-04",{"date":222,"type":22},"2030-01",{"name":44,"class":45},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":231,"targetDuration":160,"studyType":55,"phases":4,"briefSummary":233,"conditions":234,"keywords":260,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":97},"100560175","institutional-registry-of-rare-diseases-100560175","NCT06573723","Institutional Registry of Rare Diseases","Institutional Registries of Rare Diseases at Hospital Italiano de Buenos Aires (HIBA)","Inclusion Criteria:\n\n* Clinical and\u002For molecular diagnosis of any of the following rare diseases: Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn Errors of Metabolism, Eosinophilic Gastrointestinal Disorders, Hypertrophic Cardiomyopathy, Gaucher Disease, Congenital Adrenal Hyperplasia, Hereditary Angioedema, Pulmonary Hypertension, Wilson Disease, Vascular Anomalies, Mastocytosis, Multiple Endocrine Neoplasia, Inflammatory Bowel Diseases, Prader-Willi Syndrome, Hirschsprung Disease, or Cushing Syndrome.\n* Must be followed at Hospital Italiano de Buenos Aires.\n\nExclusion Criteria:\n\n\\- Refusal to participate in the study or in the informed consent process.",{"count":232,"type":22},380,"The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).\n\nMoreover, the specific goals are to generate an alert system for possible cases of RD with data from the electronic medical record, to describe the occurrence of RD in the evaluated population, to characterize the population, to describe patterns of diagnosis and treatment of RD present at the time, and to explore patient-reported outcomes.",[235,212,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259],"Rare Diseases","Sarcoidosis","Phacomatosis","Pheochromocytoma","Paraganglioma","Von Hippel-Lindau Disease","Immunoglobulin G4-Related Disease","Demyelinating Diseases","Inborn Errors of Metabolism","Eosinophilic Gastrointestinal Disorders","Hypertrophic Cardiomyopathy","Gaucher Disease","Congenital Adrenal Hyperplasia","Hereditary Angioedema","Pulmonary Hypertension","Wilson Disease","Vascular Anomalies","Mastocytosis","Multiple Endocrine Neoplasia","Inflammatory Bowel Diseases","Prader-Willi Syndrome","Hirschsprung Disease","Cushing Syndrome","HHT","Hemorrhagic Hereditary Telangiectasia",[215,261,262,237,263,264,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,259],"amyloidosis","sarcoidosis","pheochromocytoma","paraganglioma","2026-01-12",{"date":267,"type":38},"2026-01-14",{"date":269,"type":38},"2024-07-01",{"date":271,"type":22},"2034-12-31",{"name":44,"class":45},{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":281,"conditions":282,"keywords":285,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":4},"100605796","predictive-model-for-multidrug-resistance-in-patients-admitted-to-the-emergency-department-with-sepsis-100605796","NCT07167173","Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis","Inclusion Criteria\n\n* Adults aged 18 years or older.\n* Attended at the Adult Emergency Department of Hospital Italiano de Buenos Aires during the periods:\n\n  * January 1, 2017 - March 20, 2020, or\n  * May 1, 2022 - August 10, 2025.\n* Sepsis or septic shock at presentation and at least 48 hours of observation or hospital admission.\n* Bacterial cultures obtained during the initial evaluation.\n\nExclusion Criteria\n\n* No indication for antibiotic therapy within the first 48 hours of hospital admission.\n* No bacterial cultures performed within the first 48 hours of hospital admission.\n* SARS-CoV-2 infection diagnosed within the first 72 hours of hospital admission.",{"count":280,"type":22},10000,"Introduction: Timely and accurate antibiotic administration in emergency department (ED) patients with sepsis or septic shock is vital, given mortality rates of 20% and over 40%, respectively. In high antimicrobial resistance (AMR) settings, selecting effective empirical antibiotics is challenging, requiring a balance between efficacy and minimizing multidrug-resistant organism (MDRO) emergence. A predictive model estimating AMR probability could optimize antibiotic use, improve outcomes, and reduce resistance. Although risk factors are known, no single validated model exists for predicting multidrug resistance in sepsis. Accurate prediction must integrate patient history, pathogen profiles, infection source, and antibiotic characteristics.\n\nObjectives: To estimate AMR prevalence in adult ED patients with sepsis or septic shock and develop a validated predictive model estimating AMR probability and likely pathogens. The model will follow a three-phase approach: (1) predict culture positivity, (2) estimate pathogen likelihood, and (3) predict AMR. Additionally, we aim to describe individual-level statistics for both predictable and unpredictable cases based on model performance.\n\nMethods: A cross-sectional study will be conducted at Hospital Italiano's adult ED over 70 months (Jan 1, 2017-Mar 20, 2020 and May 1, 2022-Aug 10, 2025), excluding the COVID-19 period. Primary outcomes include culture positivity, bacterial species, and MDRO prevalence. Frequency analyses will use positive cultures, species, and resistance classifications (MDRO, MDR, XDR, PDR), including mechanisms (e.g., MRSA, ESBL, KPC, MBL, OXA). Denominators will include all sepsis patients and, separately, culture-positive cases. Confidence intervals (95%) will be calculated using normal approximation. Multivariate logistic regression with backward stepwise selection will identify predictors and interactions. A hierarchical model will be developed based on culture results, pathogen identification, and resistance profiles.",[283,284],"Sepsis","Septic Shock",[286,287,288],"Antimicrobial resistance","sepsis","predictive models","2025-09-03",{"date":291,"type":38},"2025-09-11",{"date":293,"type":22},"2025-10-15",{"date":295,"type":22},"2025-10-31",{"name":44,"class":45},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":304,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":97},"100171170","pulmonary-hypertension-institutional-registry-at-hospital-italiano-de-buenos-aires-100171170","NCT01501838","Pulmonary Hypertension Institutional Registry at Hospital Italiano de Buenos Aires","PH-HIBA","* Inclusion Criteria:\n\n  1. Diagnosed with PAH WHO group 1 (2022 ESC\u002FESR guidelines criteria) as the presence of a mean pulmonary artery pressure (mPAP) greater than 20 mmHg at rest with pulmonary arterial wedge pressure (PAWP) \\>15 mmHg and pulmonary vascular resistance (PVR) \\>2 WU, according to the 2022 ESC\u002FERS Guidelines for the diagnosis and treatment of pulmonary hypertension.\n  2. Included in the institutional registry of PAH of Hospital Italiano de Buenos Aires\n  3. Aged ≥18 years at the index date.\n* Exclusion Criteria History of lung transplantation surgery previously the baseline period","17 Years",{"count":306,"type":22},200,"The purpose of this study is to create a registry of patients with Pulmonary Hypertension who received medical care in the Hospital Italiano of Buenos Aires.",[309],"Hypertension, Pulmonary Arterial","2025-08-19",{"date":312,"type":38},"2025-08-24",{"date":314,"type":38},"2017-01-01",{"date":316,"type":22},"2031-06-01",{"name":44,"class":45},{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":325,"minAge":18,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":4},"100593412","precision-medicine-applied-to-the-study-of-endometrial-cancer-application-of-ngs-for-molecular-classification-100593412","NCT07006103","Precision Medicine Applied to the Study of Endometrial Cancer: Application of NGS for Molecular Classification","Precision Medicine Applied to Endometrial Cancer (EC)","Inclusion Criteria:\n\n* Patients over 18 years of age with a diagnosis of EC diagnosed by histological biopsy and surgically treated sequentially in the participating centers in the last 5 years with clinical follow-up.\n* Patients over 18 years of age, diagnosed with CE III-IV by histological biopsy, not susceptible to surgical treatment in each institution during the last 5 years in clinical follow-up. Cases with a diagnosis of carcinosarcoma (a rare subtype of endometrial carcinoma with sarcomatous transdifferentiation) are included.\n* Material blocks fixed in formalin and embedded in paraffin with a tumor volume in the paraffin block of at least 1 cm3\n\nExclusion Criteria:\n\n* The following uterine neoplasms will be excluded:\n\n  * Biphasic tumors (epithelial-mesenchymal) such as adenosarcoma.\n  * Mesenchymal neoplasms such as endometrial stromal sarcoma and leiomyosarcomas.\n  * Others: primary lymphoproliferative processes of the uterine body; neuroendocrine tumors; Gestational trophoblastic disease, secondary lesions either of the genital tract (example: cervical carcinomas with extension to the endometrium) or of distant sites (breast cancer metastasis).\n\n    * Patients with synchronous endometrial and ovarian carcinoma\n    * For technical reasons, they will be excluded\n  * tumors smaller than 0.2 cm in which sufficient material cannot be obtained for immunohistochemical and molecular biology determinations.\n  * Tumors with severe artifacts due to poor processing, such as autolysis.\n  * Samples with low-quality DNA\n\n    * Patients operated on outside participating centers.\n    * Patients under 18 years of age.\n    * Patients with primary non-surgical treatments (neoadjuvant chemotherapy).","FEMALE",{"count":327,"type":22},400,"In recent years, knowledge about cancer biology has expanded significantly. The study of gene expression profiles has revealed the heterogeneous nature and potential reclassification of the various tumor subtypes based on specific genetic alterations. This is of great importance since it allows a therapeutic approach more directed to the intrinsic characteristics of each tumor (precision medicine).\n\nIntegrating clinicopathological information with molecular classification could provide new guidelines when approaching patients with EC, both in preoperative assessment and in adjuvant treatment and surveillance.\n\nThe application of molecular classification in endometrial carcinomas shows a subgroup of patients with an excellent prognosis, corresponding to the POLEmut subgroup that could be reclassified with eventual therapeutic de-escalation.\n\nThe clinical guidelines for the management of patients with endometrial cancer proposed by ESGO\u002FESTRO\u002FESP in 2020 recommend the use of this new classification, and warn that clinical management may be modified by the molecular classification in scenarios where adjuvant chemotherapy is considered (high-grade\u002Fhigh-risk disease).",[330],"Endometrial Cancer, Endometrial Neoplasm",[332,333,334],"endometrial cancer","molecular classification","POLEmut subgroup","2025-06-04",{"date":337,"type":38},"2025-06-08",{"date":339,"type":22},"2025-06",{"date":341,"type":22},"2026-12",{"name":44,"class":45},{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":351,"conditions":352,"keywords":354,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":97},"100190992","institutional-registry-of-haemorrhagic-hereditary-telangiectasia-100190992","NCT01761981","Institutional Registry of Haemorrhagic Hereditary Telangiectasia","Inclusion Criteria:\n\n1. Patients with HHT defined.\n2. Followed in Unidad HHT of Hospital Italiano de Buenos Aires.\n\nExclusion Criteria:\n\n1\\. Denied to participated in the registry or inform consent process.",{"count":350,"type":22},590,"The purpose of this study is to create an institutional and population-based registry of Haemorrhagic Hereditary Telangiectasia with a prospective survey based on epidemiological data, risk factors, diagnosis, prognosis, treatment, monitoring and survival.\n\nThis study will also describe the occurrence of Haemorrhagic Hereditary Telangiectasia in the population of HIBA in the Central Hospital, as well as the characteristics of clinical presentation and evolution.",[353],"Haemorrhagic Hereditary Telangiectasia",[353,355,356,258],"Rendu Osler Weber Syndrome","Osler Weber Rendu Syndrome","2025-05-19",{"date":359,"type":38},"2025-05-22",{"date":361,"type":38},"2010-01-01",{"date":363,"type":22},"2035-12",{"name":44,"class":45},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":376,"conditions":377,"keywords":382,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":97},"100568634","ventilatory-settings-and-monitoring-variables-associated-with-weaning-failure-in-critically-ill-patients-100568634","NCT06683781","Ventilatory Settings and Monitoring Variables Associated With Weaning Failure in Critically Ill Patients","Ventilatory Settings and Monitoring Variables Associated With Weaning Failure in Critically Ill Patients: A Retrospective Study","WEAN-FAIL","Inclusion Criteria:\n\n* Over 18 years\n* MV for at least 48 hours, regardless of the cause of onset\n* Undergone at least one extubation, regardless of the outcome\n* At least one spontaneous breathing trial (SBT) during their ICU stay, regardless of the outcome\n\nExclusion Criteria:\n\n* MV records containing incorrect or inconsistent data\n* did not have adequate or continuous monitoring during the weaning process","100 Years",{"count":375,"type":22},1077,"Mechanical ventilation (MV) is essential in managing acute respiratory failure. Its duration is a crucial aspect since both, unnecessary prolongation and premature withdrawal have deleterious effects on patient outcomes in the ICU. The process of weaning refers to the set of procedures and evaluations carried out to discontinue MV. Regardless of the definition used, within the population undergoing weaning, there is a group of patients who successfully pass the daily screening but fail the spontaneous breathing trial (SBT) or the separate attempt (SA). In Argentina, this figure is 39.5%, and 31.4% in patients with COVID-19. On the other hand, another group of patients successfully passes the SA, is extubated, but fails in post-extubation. This failure rate varies in the literature, ranging from approximately 10 to 20%. In our country, this figure is 16% in the general population and rises to 29.7% in COVID-19 patients. Additionally, this population is divided into those who cannot tolerate ventilation without an artificial airway due to upper airway patency issues (such as laryngeal edema), i.e., \"airway failure,\" and those who experience acute respiratory failure. In 2023, the WEAN SAFE study reported novel findings regarding variables associated with weaning failure. In multivariable analysis, it was found that the MV settings and monitoring variables at the time of the first SBT - respiratory rate, positive end-expiratory pressure (PEEP), dynamic airway pressure difference (peak pressure (Ppeak) minus PEEP) on the day of the SA - were associated with weaning failure. In this context, the investigators will conduct a retrospective cohort study, whose primary objective will be to assess which MV settings and monitoring variables are associated with weaning failure.\n\n\\*\\*Primary Objective\\*\\* To determine if there are any MV settings or monitoring variables that are associated with extubation failure.\n\n\\*\\*Secondary Objective\\*\\* To determine if there are any MV settings or monitoring variables that are associated with failure in the first SBT.",[378,379,380,381],"Mechanical Ventilation","Weaning Failure","Weaning Failure of Mechanical Ventilation","Intensive Care Unit ICU",[383,384],"weaning failure","mechanical ventilation","2025-03-12",{"date":387,"type":38},"2025-03-17",{"date":389,"type":38},"2024-12-01",{"date":391,"type":22},"2026-08-01",{"name":44,"class":45},{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":17,"minAge":304,"maxAge":4,"enrollmentInfo":399,"targetDuration":401,"studyType":55,"phases":4,"briefSummary":402,"conditions":403,"keywords":407,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":422,"locationsCount":97},"100564881","international-surveillance-of-antimicrobial-resistance-in-cirrhosis-related-infections-100564881","NCT06634940","International Surveillance of Antimicrobial Resistance in Cirrhosis-Related Infections","Inclusion Criteria:\n\n* Episodes of culture-confirmed bacterial infections\n* Patients diagnosed with cirrhosis\n* Infections diagnosed either at the time of hospital admission or during hospitalization\n\nExclusion Criteria:\n\n* History of solid organ or hematopoietic stem cell transplantation\n* Declined to participate in the study",{"count":400,"type":22},1000,"1 Week","What is this study about?\n\nThis study tracks antibiotic resistance in patients with cirrhosis who develop bacterial infections. Cirrhosis is a condition where the liver is severely scarred, and people with cirrhosis are at high risk for serious bacterial infections.\n\nWhy is this study important?\n\nBacterial infections are common in patients with cirrhosis, affecting 25-46% of those who are hospitalized. These infections can be life-threatening, with 1 in 4 patients dying from complications. Many of these infections are becoming harder to treat because the bacteria are resistant to antibiotics. Infections caused by resistant bacteria are increasing, which makes finding the right antibiotic quickly even more difficult.\n\nIn other regions of the world, guidelines exist to help doctors choose the right antibiotics for cirrhosis patients. However, in Latin America, we don't have specific guidelines for our region, and doctors currently rely on recommendations from the U.S. or Europe. These guidelines may not reflect the local patterns of bacterial infections and resistance we see here.\n\nWhat is the goal of this study?\n\nThe main goal of this study is to create a long-term system to track how bacteria respond to antibiotics in patients with cirrhosis in Latin America. By collecting data from hospitals across different countries, we aim to:\n\n* Identify how many infections are caused by multidrug-resistant bacteria.\n* Understand how antibiotics (such as ceftriaxone, vancomycin, and carbapenems) act against these infections.\n* Generate reports informing bacterial resistance patterns to help doctors make better patient treatment decisions.\n\nWhat do we hope to achieve?\n\nWe hope the data we collect will help develop guidelines for patients with cirrhosis in Latin America. These guidelines will ensure that doctors use the most effective antibiotics based on real-time data from our region. This should improve patient outcomes and help prevent the spread of resistant bacteria.",[404,405,406],"Cirrhosis","Bacterial Infections","Multidrug Resistance",[408,409,410,411,412,413,414,415],"antibiotics","empirical treatment","methicillin-resistant Staphylococcus aureus","extended-spectrum beta-lactamase-producing organisms","Carbapenemase-Producing Enterobacteriaceae","de-escalation","guidelines","empiric antibiotics","2024-10-08",{"date":418,"type":38},"2024-10-10",{"date":420,"type":38},"2020-11-15",{"date":316,"type":22},{"name":44,"class":45},""]